Literature DB >> 6366560

Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.

C Ponticelli, P Zucchelli, E Imbasciati, L Cagnoli, C Pozzi, P Passerini, C Grassi, D Limido, S Pasquali, T Volpini.   

Abstract

Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 +/- 18.2 months for the treated group and 37.0 +/- 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function during follow-up, whereas in the control group the reciprocal of the plasma creatinin level, which is proportional to the creatinine clearance, decreased significantly (P = 0.00017) after two years of follow-up. Side effects were minimal in all treated patients except two, who were dropped from the study because of peptic ulcer and gastric intolerance to chlorambucil. We conclude that steroid and chlorambucil treatment for six months favors remission of the nephrotic syndrome in adults with idiopathic membranous nephropathy and can preserve renal function for at least some years.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6366560     DOI: 10.1056/NEJM198404123101503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

1.  Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Authors:  Chadwick E Barnes; William A Wilmer; Raul A Hernandez; Christopher Valentine; Leena S Hiremath; Tibor Nadasdy; Anjali A Satoskar; Rose L Shim; Brad H Rovin; Lee A Hebert
Journal:  Nephron Clin Pract       Date:  2011-07-08

2.  Immunosuppression in idiopathic membranous nephropathy: A double-edge sword.

Authors:  Vincenzo L'Imperio; Elena Ajello; Maurizio Garozzo; Antonella Tosoni; Franco Ferrario; Fabio Pagni
Journal:  Int J Immunopathol Pharmacol       Date:  2016-07-06       Impact factor: 3.219

3.  Long-term effects of steroid and cytostatic treatment on the clinical course of idiopathic membranous glomerulonephritis (retrospective study).

Authors:  G Mohácsi; A Magori; S Sonkodi
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

Review 4.  Therapy of idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini
Journal:  Springer Semin Immunopathol       Date:  1987

Review 5.  The treatment of immune glomerular disease.

Authors:  D G Williams
Journal:  Springer Semin Immunopathol       Date:  1987

6.  Idiopathic membranous glomerulonephritis: aspects of geographical differences.

Authors:  S Abe; Y Amagasaki; K Konishi; E Kato; S Iyori; H Sakaguchi
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

7.  Clinical review of idiopathic versus hepatitis B surface antigen related forms of membranous glomerulonephritis.

Authors:  S Ozen; U Saatci; A Bakkaloglu; N Besbas
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

8.  Ponticelli regimen in idiopathic nephrotic syndrome.

Authors:  U Das; K V Dakshinamurty; N Prasad
Journal:  Indian J Nephrol       Date:  2009-04

9.  Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan.

Authors:  Yu-Huei Liu; Cheng-Hsu Chen; Shih-Yin Chen; Ying-Ju Lin; Wen-Ling Liao; Chang-Hai Tsai; Lei Wan; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2010-10-11       Impact factor: 8.410

10.  [Drug treatment of chronic glomerulonephritis: contra].

Authors:  K Andrassy; R Waldherr; E Ritz
Journal:  Klin Wochenschr       Date:  1985-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.